We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Treatment for Smallpox

By Biotechdaily staff writers
Posted on 22 Sep 2005
Researchers have identified an antibody in humans that quickly fights the smallpox virus, representing a new treatment for the disease.

By studying blood samples from people who had received the smallpox vaccine, Shane Crotty, Ph.D., a viral disease expert, and his team at the La Jolla Institute for Allergy & Immunology (LIAI, San Diego, CA, USA) discovered the H3 protein, which elicits a particularly strong human antibody response. More...
Their findings were reported in the September 2005 issue of the Journal of Virology.

"Out of the 200 or so proteins contained in the smallpox virus, we found that the H3 protein is a major target for antibodies that kill the virus,” said Dr. Crotty. No actual smallpox virus was used in the studies in order to avoid any potential danger of transmission.

The research team used new techniques that made it easier to identify and isolate antibodies from the blood of immunized humans. Then they carefully screened for the antibodies that fight the smallpox virus. Next they tested their findings by creating a batch of the anti-H3 protein antibodies, which they injected into mice. "We were able to protect them from a strain of vaccinia pox virus that is very similar to smallpox and which is lethal to mice,” noted Dr. Crotty.

The U.S. National Institutes of Health (Bethesda, MD, USA) is now funding further research by Dr. Crotty to better understand the molecular processes surrounding the finding. One focus of the research will be to fully develop anti-H3 antibodies in the lab that can be given to humans.

"We will be working to further characterize and develop the use of this antibody as a treatment for smallpox,” added Dr. Crotty. "Unlike the vaccine, the antibody would work to provide immediate, although short-term, protection, similar to how an antibiotic treats and for a short time protects against a bacterial infection.”




Related Links:
La Jolla Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.